[Abandon LDL cholesterol target levels]

Area of Science:

• Cardiology
• Pharmacology
• Public Health

Background:

• Current guidelines for stable cardiovascular disease (CVD) management specify targets for LDL cholesterol and blood pressure.
• Observational studies indicate that many patients do not achieve these targets despite intensive medication.
• Specifically, LDL cholesterol levels below 1.7 mmol/l (European guidelines) or 2.5 mmol/l (Dutch guidelines) are often unattainable with statin therapy.

Purpose of the Study:

• To evaluate current approaches to managing cardiovascular disease, focusing on LDL cholesterol targets.
• To assess the efficacy and recommendations for cholesterol-lowering drugs in preventive therapy.
• To provide guidance on statin prescription based on clinical trial evidence.

Main Methods:

• Review of existing guidelines for cardiovascular disease management.
• Analysis of observational studies on treatment adherence and target achievement.
• Evaluation of clinical trial data for statins, ezetimibe, and fibrates.

Main Results:

• Many patients fail to reach recommended LDL cholesterol targets with current statin therapy.
• Recent US guidelines advocate for statin therapy without specific LDL cholesterol level targets.
• Ezetimibe and fibrates lack demonstrated clinical efficacy for preventive therapy and are not recommended.

Conclusions:

• Physicians should prescribe statins at doses consistent with clinical trials.
• Statin dosage should be independent of the achieved LDL cholesterol level.
• Current evidence does not support the use of ezetimibe or fibrates as primary preventive therapy for CVD.